/AIMD
AIMD Stock - Ainos, Inc.
Healthcare|BiotechnologyNASDAQ
$2.11+2.93%
+$0.06 (+2.93%) • Dec 19
41
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.8
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.24
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.32
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AIMD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.09 – $2.13
TARGET (TP)$2.43
STOP LOSS$1.94
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.40
52W High$5.00
52W Low$1.78
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $20,729 | $122,112 | $3.52M | $594,563 | $16,563 |
| Gross Profit | $-31,866 | $-253,733 | $1.41M | $410,382 | $5,286 |
| Gross Margin | -153.7% | -207.8% | 39.9% | 69.0% | 31.9% |
| Operating Income | $-13,841,204 | $-13,206,396 | $-13,976,212 | $-3,867,426 | $-1,440,435 |
| Net Income | $-14,863,161 | $-13,770,549 | $-14,006,690 | $-3,888,661 | $-1,450,623 |
| Net Margin | -71702.3% | -11277.0% | -398.0% | -654.0% | -8758.2% |
| EPS | $-1.56 | $-3.36 | $-5.14 | $-2.59 | $-2.69 |
Company Overview
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
AIMDBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.64
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | — | $-0.64 | — | — |
Q3 2025 | Aug 13, 2025 | — | $-0.99 | — | — |
Q2 2025 | May 12, 2025 | — | $-1.05 | — | — |
Q1 2025 | Mar 7, 2025 | — | $-1.30 | — | — |
Q4 2024 | Nov 6, 2024 | — | $-1.65 | — | — |
Q3 2024 | Aug 5, 2024 | — | $-2.45 | — | — |
Q2 2024 | May 13, 2024 | — | $-2.85 | — | — |
Q1 2024 | Mar 8, 2024 | — | $-1.37 | — | — |
Q1 2024 | Feb 7, 2024 | — | $-0.73 | — | — |
Q3 2023 | Aug 11, 2023 | — | $-3.00 | — | — |
Q2 2023 | May 12, 2023 | — | $-3.25 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-2.75 | — | — |
Q4 2022 | Nov 7, 2022 | — | $-12.75 | — | — |
Q3 2022 | Aug 15, 2022 | — | $-0.25 | — | — |
Q2 2022 | May 16, 2022 | — | $-3.75 | — | — |
Q1 2022 | Mar 21, 2022 | — | $-0.01 | — | — |
Q4 2021 | Nov 15, 2021 | — | $-37.48 | — | — |
Q3 2021 | Aug 20, 2021 | — | $-3.75 | — | — |
Latest News
Ainos Q3 EPS $(0.64) Up From $(1.65) YoY, Sales $2.167K
📈 PositiveBenzinga•Nov 13, 2025, 09:45 PM
Ainos Enters Into Fourth Addendum Agreement To The Product Development Agreement With Taiwan Carbon Nano Technology; To Amend Fee For Exclusive Use Of Patents Of $50K/Month For Two Years
📈 PositiveBenzinga•Oct 17, 2025, 08:17 PM
Ainos Collaborates With NEXCOM International To Integrate Ainos' AI Nose Technology With NEXCOM's Industrial Edge Computing Platforms
📈 PositiveBenzinga•Oct 14, 2025, 12:33 PM
Ainos Secures Seven New Patents In Europe, Germany, Taiwan, And China, Enhancing Its AI Nose Digital Olfaction Platform For Robotics Applications
📈 PositiveBenzinga•Sep 30, 2025, 12:32 PM
Ainos Signs Distribution Agreement With Topco Scientific For Commercialization Of Ainos' AI Nose Platform
📈 PositiveBenzinga•Sep 16, 2025, 01:32 PM
Ainos Posts Wider Loss in Fiscal Q2
📉 NegativeThe Motley Fool•Aug 13, 2025, 10:26 PM
Frequently Asked Questions about AIMD
What is AIMD's current stock price?
Ainos, Inc. (AIMD) is currently trading at $2.11 per share. The stock has moved +2.93% today.
What is the analyst price target for AIMD?
No analyst price targets are currently available for this stock.
What sector is Ainos, Inc. in?
Ainos, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is AIMD's market cap?
Ainos, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does AIMD pay dividends?
No, Ainos, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADTX
Aditxt, Inc.
$1.17
Mkt Cap: $0.0B
ANL
Adlai Nortye Ltd.
$1.52
Mkt Cap: $0.0B
ATHA
Athira Pharma, Inc.
$6.97
Mkt Cap: $0.0B
BLRX
BioLineRx Ltd.
$3.04
Mkt Cap: $0.0B
DARE
Daré Bioscience, Inc.
$2.09
Mkt Cap: $0.0B
FBLG
FibroBiologics, Inc. Common Stock
$0.26
Mkt Cap: $0.0B
GOVX
GeoVax Labs, Inc.
$0.16
Mkt Cap: $0.0B
ICU
SeaStar Medical Holding Corporation
$0.24
Mkt Cap: $0.0B
MBRX
Moleculin Biotech, Inc.
$3.90
Mkt Cap: $0.0B
THAR
Tharimmune, Inc.
$2.32
Mkt Cap: $0.1B
Explore stocks similar to AIMD for comparison